Sensei Biotherapeutics Inc
SNSE8.860USD
-0.260-2.85%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
11.18MMarket Cap
LossP/E TTM
More Details of Sensei Biotherapeutics Inc Company
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Sensei Biotherapeutics Inc Info
Ticker SymbolSNSE
Company nameSensei Biotherapeutics Inc
IPO dateFeb 04, 2021
CEOCelebi (John K)
Number of employees14
Security typeOrdinary Share
Fiscal year-endFeb 04
Address1405 Research Blvd, Suite 125
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone12402438000
Websitehttps://www.senseibio.com/
Ticker SymbolSNSE
IPO dateFeb 04, 2021
CEOCelebi (John K)
Company Executives of Sensei Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Gregory (Tom) Ricks
Mr. Thomas Gregory (Tom) Ricks
Independent Director
Independent Director
17.27K
+1.74%
Mr. Bob Holmen
Mr. Bob Holmen
Independent Director
Independent Director
1.28K
+21.10%
Mr. William R. (Bill) Ringo
Mr. William R. (Bill) Ringo
Independent Chairman of the Board
Independent Chairman of the Board
1.17K
+46.62%
Mr. Edward van Der Horst, Ph.D.
Mr. Edward van Der Horst, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John K. Celebi
Mr. John K. Celebi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. James Peyer, Ph.D.
Dr. James Peyer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Josiah Craver
Mr. Josiah Craver
Senior Vice President of Finance, Principal Financial and Accounting Officer
Senior Vice President of Finance, Principal Financial and Accounting Officer
--
--
Mr. Kristian F. Humer
Mr. Kristian F. Humer
Independent Director
Independent Director
--
--
Mr. Michael Biega
Mr. Michael Biega
Investor Relations
Investor Relations
--
--
Ms. Stephanie Krebs
Ms. Stephanie Krebs
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Gregory (Tom) Ricks
Mr. Thomas Gregory (Tom) Ricks
Independent Director
Independent Director
17.27K
+1.74%
Mr. Bob Holmen
Mr. Bob Holmen
Independent Director
Independent Director
1.28K
+21.10%
Mr. William R. (Bill) Ringo
Mr. William R. (Bill) Ringo
Independent Chairman of the Board
Independent Chairman of the Board
1.17K
+46.62%
Mr. Edward van Der Horst, Ph.D.
Mr. Edward van Der Horst, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John K. Celebi
Mr. John K. Celebi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. James Peyer, Ph.D.
Dr. James Peyer, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
H&S Investments I, L.P.
17.55%
Cambrian BioPharma Inc
12.30%
Ikarian Capital LLC
1.78%
Ricks (Thomas Gregory)
1.37%
Catalio Capital Management, LP
1.17%
Other
65.83%
Shareholders
Shareholders
Proportion
H&S Investments I, L.P.
17.55%
Cambrian BioPharma Inc
12.30%
Ikarian Capital LLC
1.78%
Ricks (Thomas Gregory)
1.37%
Catalio Capital Management, LP
1.17%
Other
65.83%
Shareholder Types
Shareholders
Proportion
Corporation
29.85%
Hedge Fund
2.61%
Individual Investor
2.23%
Venture Capital
1.17%
Investment Advisor
0.11%
Investment Advisor/Hedge Fund
0.09%
Research Firm
0.07%
Other
63.87%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
43
41.34K
3.28%
-125.80K
2025Q2
53
520.16K
41.24%
-84.46K
2025Q1
65
592.04K
42.15%
-83.66K
2024Q4
67
10.99M
43.71%
-5.76M
2024Q3
76
10.87M
43.20%
-6.55M
2024Q2
87
10.77M
42.86%
-5.93M
2024Q1
113
11.00M
41.97%
-8.17M
2023Q4
121
11.57M
44.26%
-7.84M
2023Q3
133
11.85M
44.62%
-7.83M
2023Q2
140
13.37M
47.63%
-5.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
H&S Investments I, L.P.
221.30K
17.55%
--
--
Mar 18, 2025
Cambrian BioPharma Inc
182.66K
14.48%
+223.00
+0.12%
Mar 18, 2025
Ikarian Capital LLC
22.50K
1.78%
-1.00
-0.00%
Jun 30, 2025
Ricks (Thomas Gregory)
17.27K
1.37%
+296.00
+1.74%
Mar 18, 2025
Catalio Capital Management, LP
14.72K
1.17%
-1.00
-0.01%
Jun 30, 2025
Celebi (John)
4.09K
0.32%
+1.24K
+43.55%
Mar 18, 2025
Van-der Horst (Edward)
2.36K
0.19%
+705.00
+42.52%
Mar 18, 2025
Holmen (Bob)
1.28K
0.1%
+223.00
+21.10%
Mar 18, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 13, 2025
Merger
20→1
Date
Type
Ratio
Jun 13, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Sensei Biotherapeutics Inc?
The top five shareholders of Sensei Biotherapeutics Inc are:
H&S Investments I, L.P. holds 221.30K shares, accounting for 17.55% of the total shares.
Cambrian BioPharma Inc holds 182.66K shares, accounting for 14.48% of the total shares.
Ikarian Capital LLC holds 22.50K shares, accounting for 1.78% of the total shares.
Ricks (Thomas Gregory) holds 17.27K shares, accounting for 1.37% of the total shares.
Catalio Capital Management, LP holds 14.72K shares, accounting for 1.17% of the total shares.
H&S Investments I, L.P. holds 221.30K shares, accounting for 17.55% of the total shares.
Cambrian BioPharma Inc holds 182.66K shares, accounting for 14.48% of the total shares.
Ikarian Capital LLC holds 22.50K shares, accounting for 1.78% of the total shares.
Ricks (Thomas Gregory) holds 17.27K shares, accounting for 1.37% of the total shares.
Catalio Capital Management, LP holds 14.72K shares, accounting for 1.17% of the total shares.
What are the top three shareholder types of Sensei Biotherapeutics Inc?
The top three shareholder types of Sensei Biotherapeutics Inc are:
H&S Investments I, L.P.
Cambrian BioPharma Inc
Ikarian Capital LLC
H&S Investments I, L.P.
Cambrian BioPharma Inc
Ikarian Capital LLC
How many institutions hold shares of Sensei Biotherapeutics Inc (SNSE)?
As of 2025Q3, 43 institutions hold shares of Sensei Biotherapeutics Inc, with a combined market value of approximately 41.34K, accounting for 3.28% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -37.96%.
What is the biggest source of revenue for Sensei Biotherapeutics Inc?
In --, the -- business generated the highest revenue for Sensei Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
